Jean-Francois Deleuze

USPTO Granted Patents = 9 (Patent Applications = 3)

Average Co-Inventor Count = 6.5

ph-index = 1

Location History:

Paris, FR (2011)
Combs la Ville, FR (2007 - 2013)

Company Filing History:

8 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

Years Active: 2007-2013

Loading Chart...

9 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8420321 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2013-04-16),

2. 8198022 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2012-06-12),

3. 8084198 - Use of a GIP promoter polymorphism (2011-12-27),

4. 7985562 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism (2011-07-26),

5. 7892744 - Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders (2011-02-22),

6. 7888020 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2011-02-15),

7. 7785781 - Method of diagnosis of a predisposition to develop thrombotic disease and its uses (2010-08-31),

8. 7560290 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2009-07-14),

9. 7262273 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2007-08-28),

Title: The Innovations of Jean-Francois Deleuze

Introduction

Jean-Francois Deleuze is a notable inventor based in Combs la Ville, France. He has made significant contributions to the field of medical science, particularly in identifying risks associated with thrombogenic disorders and diabetes. With a total of nine patents to his name, Deleuze's work has the potential to impact patient care and treatment options.

Latest Patents

One of his latest patents is a method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism. This invention aims to identify risks for conditions such as atrial fibrillation, stroke, and coronary heart disease. Another significant patent involves the association of the EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis or pulmonary embolism. This method helps in identifying an increased risk for these conditions based on specific amino acid exchanges in the EDG5 protein.

Career Highlights

Throughout his career, Jean-Francois Deleuze has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis. His work has been instrumental in advancing medical research and developing innovative solutions for complex health issues.

Collaborations

Deleuze has collaborated with notable professionals in his field, including Detlef Kozian and Sylvain Ricard. These partnerships have contributed to the success of his inventions and the advancement of medical knowledge.

Conclusion

Jean-Francois Deleuze's contributions to medical science through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the identification and treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

3 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.